JPMorgan Upgrades Vir Biotechnology (VIR) to Overweight, 'Underappreciated Link Between Phase 2 PENINSULA & Mainland Flu Prevention Market'
Tweet Send to a Friend
(Updated - March 6, 2023 6:32 AM EST)
JPMorgan analyst Eric Joseph upgraded Vir Biotechnology (NASDAQ: VIR) from Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
JPMorgan analyst Eric Joseph upgraded Vir Biotechnology (NASDAQ: VIR) from Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
